ATRA
NASDAQ
$8.63
Atara Biotherapeutics Inc (ATRA)
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $13.67 (+58.40%)
Market Cap
$73M
Free Cash Flow Yield
-35.55%
Beta (5Y)
1.38
Price Chart
Valuation
Market Cap$73M
Forward P/E3.63
P/S3.13
P/B16.14
Profitability
Total Revenue (TTM)$23M
Gross Profit (TTM)$16M
EBITDA-$5.96M
Profit Margin-40.9%
Operating Margin-653%
EPS-$1.21
Financial Health
Free Cash Flow Yield-35.55%
Growth & Risk
EPS 5Y CAGR-58.48%
FCF 5Y CAGR-32.51%
Beta (5Y)1.38
Sharpe Ratio0.56